2026 International Fall Summit
October 28, 2026 | 12:00 PM EST
- Home
- Clinical Resources Search
- Overview of BTCEs: Engaging with Bispecific T-Cell Engagers
Engaging with Bispecific T-Cell Engagers
Last Updated: November 20, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 04/23/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Up Close with Linvoseltamab
Last Updated: 05/16/2025
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
Cyclophosphamide, Bortezomib, and Dexamethasone
Last Updated: 05/12/2026
Sirolimus
Last Updated: 05/11/2026
Tacrolimus
Last Updated: 05/11/2026